Fitxa persona

Dr. José Luis García Giménez holds a Bachelor's degree in Chemistry (2002), a Bachelor's degree in Biochemistry (2004), and a PhD in Chemistry from the University of Valencia. He is currently an Assistant Professor in the Department of Physiology at the Faculty of Medicine and Dentistry, a Postdoctoral Researcher at CIBER-ISCIII in Rare Diseases, and Principal Investigator of the emerging group in Epigenetics and Translational Epigenomics at INCLIVA.

He has published over 125 scientific articles, 60 presentations at international conferences, and 7 book chapters, with over 3,000 citations. He is the editor-in-chief of the books "Epigenetic Biomarkers and Diagnostics" and "Epigenetics in Precision Medicine" (Academic Press, Elsevier).

Throughout his career, he has participated in 37 funded research projects (15 as Principal Investigator) within the ISCIII, the National Research Plan, and regional projects. He is the inventor of five patent families, notably EP15382319.0 and EP16382509.4, granted in the USA, China, Hong Kong, Japan, and Europe, and transferred to industry. He is a co-author of the SepAsT medical software, registered with the OMPM (M4155197).

He is a founding partner of EpiDisease S.L., the first spin-off company of CIBER-ISCIII and INCLIVA, dedicated to the development of IVD tests based on epigenetic biomarkers. His patent on circulating histones for sepsis received the European Commission's Seal of Excellence (EIC Accelerator Challenge).

He has received nine international awards, including the Leopold Flohé Redox Pioneer Award (2023) and the European Young Investigation Award (2009). His entrepreneurial work has been recognized by the Massachusetts Institute of Technology (LinQ Idea2 Global 2016 and 2017), CaixaImpulse of the Fundació La Caixa and MindtheGap of the Fundación Botín.